Status:

NOT_YET_RECRUITING

Psoas Muscle Index (PMI) as a Predictor of Outcomes After Minimally Invasive Cardiac Surgery

Lead Sponsor:

I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio

Conditions:

Sarcopenia

Heart Valve Diseases

Eligibility:

All Genders

65-99 years

Brief Summary

Sarcopenia or muscle loss and function is a component of the frailty syndrome. In this sense, frailty is becoming an important risk factor in predicting outcomes after major surgery and is defined as ...

Detailed Description

This is a prospective, controlled, observational single-centre study of patients undergoing minimally invasive heart valve surgery at the department of minimally invasive cardiac surgery of the IRCCS ...

Eligibility Criteria

Inclusion

  • Elderly patients (≥ 65 years old)
  • Able to take consent
  • Listed for minimally invasive cardiac surgery
  • Elective and urgent procedures included
  • Able to undergo MRI

Exclusion

  • Full median sternotomy approach
  • Emergency procedures
  • Unable to take consent
  • Unable to undergo MRI

Key Trial Info

Start Date :

September 1 2024

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 1 2025

Estimated Enrollment :

25 Patients enrolled

Trial Details

Trial ID

NCT06571643

Start Date

September 1 2024

End Date

December 1 2025

Last Update

August 26 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio

Milan, Italy, 20173

Psoas Muscle Index (PMI) as a Predictor of Outcomes After Minimally Invasive Cardiac Surgery | DecenTrialz